Investment by Cancer Topic

<table>
<thead>
<tr>
<th>Topic</th>
<th>Investment</th>
<th>Projects</th>
<th>Researchers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare Cancers</td>
<td>$827K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>$3.1M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>$1.3M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>$1.8M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>$1.3M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>$568K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>$602K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>$559K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other*</td>
<td>$2.2M</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Investment by Cancer Type

<table>
<thead>
<tr>
<th>Type</th>
<th>Investment</th>
<th>Projects</th>
<th>Researchers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Systems Research</td>
<td>$213K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy &amp; Radiation</td>
<td>$501K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Metastasis</td>
<td>$1.2M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>$1.2M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Precision Medicine</td>
<td>$3.0M</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NUMBER OF PROJECTS by Cancer Types

- Blood: 39
- Brain: 31
- Breast: 29
- Prostate: 25
- Lung: 24
- Head & Neck: 21
- Rare Cancers: 18
- Liver: 16
- Other*: 14

CANCER TOPICS

- Health Systems Research: 39
- Cancer Metastasis: 31
- Precision Medicine: 29
- Immunotherapy: 28
- Cancer Biology: 27
- Cancer Drugs: 24
- Early Detection & Diagnosis: 24
- Chemotherapy & Radiation: 21
- Health Systems Research: 16
- Other*: 14

YEAR-TO-YEAR COMPARISON

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Projects</th>
<th>Researchers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021-22</td>
<td>37</td>
<td>268*</td>
</tr>
<tr>
<td>2020-21</td>
<td>37</td>
<td>202</td>
</tr>
<tr>
<td>2019-20</td>
<td>35</td>
<td>188</td>
</tr>
</tbody>
</table>

MARATHON OF HOPE CANCER CENTRES NETWORK AND THE DIGITAL HEALTH AND DISCOVERY PLATFORM

- BC: 35
- MB: 268
- ON: 268
- AB: 25
- NB: 13
- NS: 5
- SK: 8
- QC: 8
- PEI: 2
- YT: 2
- NL: 3
- AT: 3
- TOTAL: 268

This information is subject to change as we work through outstanding cases and finalize new cases. Final numbers will be reported in the 2023-24 financial year.
OUR RESEARCH PORTFOLIO AT A GLANCE

$14.1M Invested

35 Projects

268 Researchers

93 Institutions

2021 – 2022 Fiscal Year
REGIONAL NODES

BC
$4.7M INVESTED
12 PROJECTS*
61 RESEARCHERS
15 INSTITUTIONS

AB
$653K INVESTED
4 PROJECTS*
25 RESEARCHERS
14 INSTITUTIONS

PRAIRIES
$300K INVESTED
1 PROJECTS*
13 RESEARCHERS
5 INSTITUTIONS

ON
$6.3M INVESTED
22 PROJECTS*
128 RESEARCHERS
19 INSTITUTIONS

QC
$1.1M INVESTED
8 PROJECTS*
26 RESEARCHERS
15 INSTITUTIONS

ATLANTIC
$1.1M INVESTED
3 PROJECTS*
15 RESEARCHERS
12 INSTITUTIONS

*Many of our projects are pan-Canadian in nature and their research is conducted in more than one region. Thus, project totals shown here should not be added up, as their sum will equal more than 35, the total number of projects we fund.
## FUNDING PROGRAMS

<table>
<thead>
<tr>
<th>Program</th>
<th>Investment</th>
<th>Projects</th>
<th>Researchers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry Fox New Frontiers Program Project Grants</td>
<td>$9.8M</td>
<td>13</td>
<td>169</td>
</tr>
<tr>
<td>Terry Fox Translational Research Program</td>
<td>$1.5M</td>
<td>4</td>
<td>74</td>
</tr>
<tr>
<td>Terry Fox New Investigator Award</td>
<td>$928K</td>
<td>12</td>
<td>25</td>
</tr>
<tr>
<td>Marathon of Hope Cancer Centres Network Pilots</td>
<td>$1.5M</td>
<td>2</td>
<td>37</td>
</tr>
<tr>
<td>Other Programs</td>
<td>$407K</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$14.1M</strong></td>
<td><strong>35</strong></td>
<td><strong>268</strong></td>
</tr>
</tbody>
</table>

*A number of researchers work on several projects across program types. While these individuals may be counted in more than one program type, the total number displayed at the bottom reflects the individual number of researchers we fund: 268*
**CANCER TYPES†**

**Investment by Cancer Type**

- Blood: $3.1M
- Prostate: $1.8M
- Brain: $1.3M
- Breast: $1.3M
- Pediatric & Young Adult: $1.3M
- Rare Cancers: $827K
- Head & Neck: $602K
- Lung: $568K
- Liver: $559K
- Pancreatic: $526K
- Other*: $2.2M

*This category includes our investment in projects that have non-specific cancer types as well as a cumulative total of our investment in cancer types that received less than 3% of our annual funding, including ovarian cancers, gastrointestinal cancers, and sarcomas.

**Number of Projects by Cancer Type**

<table>
<thead>
<tr>
<th>Types</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>8</td>
</tr>
<tr>
<td>Breast</td>
<td>7</td>
</tr>
<tr>
<td>Blood</td>
<td>7</td>
</tr>
<tr>
<td>Pediatric &amp; Young Adult</td>
<td>5</td>
</tr>
<tr>
<td>Prostate</td>
<td>4</td>
</tr>
<tr>
<td>Liver</td>
<td>4</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>3</td>
</tr>
<tr>
<td>Colorectal</td>
<td>2</td>
</tr>
<tr>
<td>Ovarian</td>
<td>2</td>
</tr>
<tr>
<td>All Cancers</td>
<td>2</td>
</tr>
<tr>
<td>Lung</td>
<td>2</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>2</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>1</td>
</tr>
<tr>
<td>Rare Cancers</td>
<td>1</td>
</tr>
</tbody>
</table>

†Our projects are interdisciplinary by design and often apply to more than one cancer type. Our investment per cancer type is an estimation. The interdisciplinary nature of our projects also means that the number of projects by cancer type should not be added, as their sum will be more than 35, the number of projects we currently fund.
Investment by Cancer Topic

- Cancer Biology: $4.0M
- Precision Medicine: $3.0M
- Biobanking: $1.4M
- New Technologies: $1.3M
- Immunotherapy: $1.2M
- Cancer Metastasis: $1.2M
- Cancer Drugs: $918K
- Chemotherapy & Radiation: $501K
- Early Detection & Diagnosis: $326K
- Health Systems Research: $213K

TOTAL INVESTMENT: $14.1M

Number of Projects by Cancer Topic

- Cancer Biology: 16
- Precision Medicine: 14
- Immunotherapy: 7
- Cancer Metastasis: 7
- New Technologies: 7
- Biobanking: 7
- Cancer Drugs: 5
- Chemotherapy & Radiation: 3
- Health Systems Research: 2
- Early Detection & Diagnosis: 1

†Our projects are interdisciplinary by design and often apply to more than one cancer topic. Our investment per cancer topic is an estimation. The interdisciplinary nature of our projects also means that the number of projects by cancer topic should not be added, as their sum will be more than 35, the number of projects we currently fund.
The differences in numbers for projects, researchers and institutions between the fiscal years reflect new developments at TFRI as well as the regular changes that come with our annual research operations and funding cycles.

In addition to its legacy program, TFRI is now focused on operationalizing two innovative projects that embody Terry Fox’s spirit and unite the country to improve the lives of cancer patients through precision medicine: the Marathon of Hope Cancer Centres Network (MOHCCN) and the Digital Health and Discovery Platform (DHDP).

Additionally, as part of our operational cycle, some projects have been completed and their funding term has ended. Our research investment total varies annually and is based on funds received from The Terry Fox Foundation and other funders.

<table>
<thead>
<tr>
<th>Year</th>
<th>Investment</th>
<th>Projects</th>
<th>Researchers</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021-22</td>
<td>$14.1M</td>
<td>35</td>
<td>268</td>
<td>93</td>
</tr>
<tr>
<td>2020-21</td>
<td>$11.6M</td>
<td>37</td>
<td>385</td>
<td>94</td>
</tr>
<tr>
<td>2019-20</td>
<td>$21.8M</td>
<td>52</td>
<td>361</td>
<td>81</td>
</tr>
</tbody>
</table>
In the 2021-22 fiscal year, the Terry Fox Research Institute invested $1,939,579.86 in the Digital Health and Discovery Platform. Key outcomes of this investment include the development of a Pan-Canadian data governance framework that protects individual privacy and will be validated through a pilot initiative. In parallel, communication and data strategies leading to the implementation of activities to educate, inform and engage the diverse group stakeholders, to build the DHDP network and target users to stimulate the commercialization of homegrown research discoveries.

*Cases in progress as of September 2022. †Fully profiled cases (whole genome and transcription sequencing).